Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 495

1.

A study of ALK-positive pulmonary squamous-cell carcinoma: From diagnostic methodologies to clinical efficacy.

Wang H, Sun L, Sang Y, Yang X, Tian G, Wang Z, Fang J, Sun W, Zhou L, Jia L, Tsao MS, Shi H, Lin D.

Lung Cancer. 2019 Apr;130:135-142. doi: 10.1016/j.lungcan.2019.02.015. Epub 2019 Feb 18.

PMID:
30885334
2.

Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade.

Fang L, Ly D, Wang SS, Lee JB, Kang H, Xu H, Yao J, Tsao MS, Liu W, Zhang L.

J Exp Clin Cancer Res. 2019 Mar 11;38(1):123. doi: 10.1186/s13046-019-1126-y.

3.

Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer.

Laurie SA, Banerji S, Blais N, Brule S, Cheema PK, Cheung P, Daaboul N, Hao D, Hirsh V, Juergens R, Laskin J, Leighl N, MacRae R, Nicholas G, Roberge D, Rothenstein J, Stewart DJ, Tsao MS.

Curr Oncol. 2019 Feb;26(1):e81-e93. doi: 10.3747/co.26.4116. Epub 2019 Feb 1.

4.

Outcomes of Long-term Interval Rescreening with Low-Dose CT for Lung Cancer in Different Risk Cohorts.

Aggarwal R, Lam AC, McGregor M, Menezes R, Hueniken K, Tateishi H, O'Kane GM, Tsao MS, Shepherd FA, Xu W, McInnis M, Schmidt H, Liu G, Kavanagh J.

J Thorac Oncol. 2019 Feb 13. pii: S1556-0864(19)30112-1. doi: 10.1016/j.jtho.2019.01.031. [Epub ahead of print]

PMID:
30771523
5.

Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer.

Tomasini P, Mascaux C, Jao K, Labbe C, Kamel-Reid S, Stockley T, Hwang DM, Leighl NB, Liu G, Bradbury PA, Pintilie M, Tsao MS, Shepherd FA.

Clin Lung Cancer. 2018 Dec 19. pii: S1525-7304(18)30333-4. doi: 10.1016/j.cllc.2018.12.009. [Epub ahead of print]

PMID:
30770327
6.

Elevated platelet count appears to be causally associated with increased risk of lung cancer: A Mendelian randomization analysis.

Zhu Y, Wei Y, Zhang R, Dong X, Shen S, Zhao Y, Bai J, Albanes D, Caporaso NE, Landi MT, Zhu B, Chanock SJ, Gu F, Lam S, Tsao MS, Shepherd FA, Tardon A, Fernández-Somoano A, Fernandez-Tardon G, Chen C, Barnett MJ, Doherty J, Bojesen SE, Johansson M, Brennan P, McKay JD, Carreras-Torres R, Muley T, Risch A, Wichmann HE, Bickeboeller H, Rosenberger A, Rennert G, Saliba W, Arnold SM, Field JK, Davies MPA, Marcus MW, Wu X, Ye Y, Le Marchand L, Wilkens LR, Melander O, Manjer J, Brunnström H, Hung RJ, Liu G, Brhane Y, Kachuri L, Andrew AS, Duell EJ, Kiemeney LA, van der Heijden EHFM, Haugen A, Zienolddiny S, Skaug V, Grankvist K, Johansson M, Woll PJ, Cox A, Taylor F, Teare DM, Lazarus P, Schabath MB, Aldrich MC, Houlston RS, McLaughlin J, Stevens VL, Shen H, Hu Z, Dai J, Amos CI, Han Y, Zhu D, Goodman GE, Chen F, Christiani DC.

Cancer Epidemiol Biomarkers Prev. 2019 Jan 30. pii: cebp.0356.2018. doi: 10.1158/1055-9965.EPI-18-0356. [Epub ahead of print]

PMID:
30700444
7.

Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15.

Yao J, Ly D, Dervovic D, Fang L, Lee JB, Kang H, Wang YH, Pham NA, Pan H, Tsao MS, Zhang L.

J Immunother Cancer. 2019 Jan 22;7(1):17. doi: 10.1186/s40425-019-0507-2.

8.

Health-related quality of life and anxiety in the PAN-CAN lung cancer screening cohort.

Taghizadeh N, Tremblay A, Cressman S, Peacock S, McWilliams AM, MacEachern P, Johnston MR, Goffin J, Goss G, Nicholas G, Martel S, Laberge F, Bhatia R, Liu G, Schmidt H, Atkar-Khattra S, Tsao MS, Tammemagi MC, Lam SC; Pan-Canadian Early Lung Cancer Study Group.

BMJ Open. 2019 Jan 17;9(1):e024719. doi: 10.1136/bmjopen-2018-024719.

9.

ONECUT2 is a driver of neuroendocrine prostate cancer.

Guo H, Ci X, Ahmed M, Hua JT, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E, Su P, Chen S, Nguyen T, Liang Y, Zhang Y, Xu X, Xu J, Sheahan AV, Ba-Alawi W, Zhang S, Mahamud O, Vellanki RN, Gleave M, Bristow RG, Haibe-Kains B, Poirier JT, Rudin CM, Tsao MS, Wouters BG, Fazli L, Feng FY, Ellis L, van der Kwast T, Berlin A, Koritzinsky M, Boutros PC, Zoubeidi A, Beltran H, Wang Y, He HH.

Nat Commun. 2019 Jan 17;10(1):278. doi: 10.1038/s41467-018-08133-6.

10.

Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation.

Kano Y, Gebregiworgis T, Marshall CB, Radulovich N, Poon BPK, St-Germain J, Cook JD, Valencia-Sama I, Grant BMM, Herrera SG, Miao J, Raught B, Irwin MS, Lee JE, Yeh JJ, Zhang ZY, Tsao MS, Ikura M, Ohh M.

Nat Commun. 2019 Jan 15;10(1):224. doi: 10.1038/s41467-018-08115-8.

11.

Whole genomes define concordance of matched primary, xenograft, and organoid models of pancreas cancer.

Gendoo DMA, Denroche RE, Zhang A, Radulovich N, Jang GH, Lemire M, Fischer S, Chadwick D, Lungu IM, Ibrahimov E, Cao PJ, Stein LD, Wilson JM, Bartlett JMS, Tsao MS, Dhani N, Hedley D, Gallinger S, Haibe-Kains B.

PLoS Comput Biol. 2019 Jan 10;15(1):e1006596. doi: 10.1371/journal.pcbi.1006596. eCollection 2019 Jan.

12.

Systematic analyses of regulatory variants in DNase I hypersensitive sites identified two novel lung cancer susceptibility loci.

Dai J, Li Z, Amos CI, Hung RJ, Tardon A, Andrew A, Chen C, Christiani DC, Albanes D, van der Heijden EHFM, Duell E, Rennert G, James MD, Yuan JM, Field JK, Jonas M, Grankvist K, Le Marchand L, Teare MD, Schabath MB, Aldrich MC, Tsao MS, Lazarus P, Stephen L, Bojesen SE, Susanne A, Wu X, Haugen A, Vladimir J, Johansson M, Yonathan B, Fernandez-Somoano A, Kiemeney LA, Davies M, Zienolddiny S, Hu Z, Shen H.

Carcinogenesis. 2018 Dec 24. doi: 10.1093/carcin/bgy187. [Epub ahead of print]

PMID:
30590402
13.

Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer.

Yatabe Y, Dacic S, Borczuk AC, Warth A, Russell PA, Lantuejoul S, Beasley MB, Thunnissen E, Pelosi G, Rekhtman N, Bubendorf L, Mino-Kenudson M, Yoshida A, Geisinger KR, Noguchi M, Chirieac LR, Bolting J, Chung JH, Chou TY, Chen G, Poleri C, Lopez-Rios F, Papotti M, Sholl LM, Roden AC, Travis WD, Hirsch FR, Kerr KM, Tsao MS, Nicholson AG, Wistuba I, Moreira AL.

J Thorac Oncol. 2019 Mar;14(3):377-407. doi: 10.1016/j.jtho.2018.12.005. Epub 2018 Dec 18.

PMID:
30572031
14.

Canadian perspectives: update on inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.

Melosky B, Cheema P, Agulnik J, Albadine R, Bebb DG, Blais N, Burkes R, Butts C, Card PB, Chan AMY, Hirsh V, Ionescu DN, Juergens R, Morzycki W, Poonja Z, Sangha R, Tehfe M, Tsao MS, Vincent M, Xu Z, Liu G.

Curr Oncol. 2018 Oct;25(5):317-328. doi: 10.3747/co.25.4379. Epub 2018 Oct 31. Review.

15.

LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non-small-cell Lung Cancer.

Seymour L, Le Teuff G, Brambilla E, Shepherd FA, Soria JC, Kratzke R, Graziano S, Douillard JY, Rosell R, Reiman A, Lacas B, Lueza B, Aviel-Ronen S, McLeer A, Le Chevalier T, Pirker R, Filipits M, Dunant A, Pignon JP, Tsao MS; LACE-Bio Steering Committee.

Clin Lung Cancer. 2019 Mar;20(2):66-73.e6. doi: 10.1016/j.cllc.2018.10.001. Epub 2018 Oct 11.

PMID:
30414783
16.

Predicting Malignancy Risk of Screen-Detected Lung Nodules-Mean Diameter or Volume.

Tammemagi M, Ritchie AJ, Atkar-Khattra S, Dougherty B, Sanghera C, Mayo JR, Yuan R, Manos D, McWilliams AM, Schmidt H, Gingras M, Pasian S, Stewart L, Tsai S, Seely JM, Burrowes P, Bhatia R, Haider EA, Boylan C, Jacobs C, van Ginneken B, Tsao MS, Lam S; Pan-Canadian Early Detection of Lung Cancer Study Group.

J Thorac Oncol. 2019 Feb;14(2):203-211. doi: 10.1016/j.jtho.2018.10.006. Epub 2018 Oct 25.

PMID:
30368011
17.

Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.

Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH Jr, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB 2nd, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM.

J Thorac Oncol. 2018 Nov;13(11):1655-1667. doi: 10.1016/j.jtho.2018.08.2036. Epub 2018 Sep 25.

PMID:
30266660
18.

Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity.

Ferreiro-Iglesias A, Lesseur C, McKay J, Hung RJ, Han Y, Zong X, Christiani D, Johansson M, Xiao X, Li Y, Qian DC, Ji X, Liu G, Caporaso N, Scelo G, Zaridze D, Mukeriya A, Kontic M, Ognjanovic S, Lissowska J, Szołkowska M, Swiatkowska B, Janout V, Holcatova I, Bolca C, Savic M, Ognjanovic M, Bojesen SE, Wu X, Albanes D, Aldrich MC, Tardon A, Fernandez-Somoano A, Fernandez-Tardon G, Le Marchand L, Rennert G, Chen C, Doherty J, Goodman G, Bickeböller H, Wichmann HE, Risch A, Rosenberger A, Shen H, Dai J, Field JK, Davies M, Woll P, Teare MD, Kiemeney LA, van der Heijden EHFM, Yuan JM, Hong YC, Haugen A, Zienolddiny S, Lam S, Tsao MS, Johansson M, Grankvist K, Schabath MB, Andrew A, Duell E, Melander O, Brunnström H, Lazarus P, Arnold S, Slone S, Byun J, Kamal A, Zhu D, Landi MT, Amos CI, Brennan P.

Nat Commun. 2018 Sep 25;9(1):3927. doi: 10.1038/s41467-018-05890-2.

19.

Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma.

Yu H, Chen Z, Ballman KV, Watson MA, Govindan R, Lanc I, Beer DG, Bueno R, Chirieac LR, Chui MH, Chen G, Franklin WA, Gandara DR, Genova C, Brovsky KA, Joshi MM, Merrick DT, Richards WG, Rivard CJ, Harpole DH, Tsao MS, van Bokhoven A, Shepherd FA, Hirsch FR.

J Thorac Oncol. 2019 Jan;14(1):25-36. doi: 10.1016/j.jtho.2018.09.006. Epub 2018 Sep 22.

PMID:
30253973
20.

Omega-3 Fatty Acids Prevent Early Pancreatic Carcinogenesis via Repression of the AKT Pathway.

Ding Y, Mullapudi B, Torres C, Mascariñas E, Mancinelli G, Diaz AM, McKinney R, Barron M, Schultz M, Heiferman M, Wojtanek M, Adrian K, DeCant B, Rao S, Ouellette M, Tsao MS, Bentrem DJ, Grippo PJ.

Nutrients. 2018 Sep 12;10(9). pii: E1289. doi: 10.3390/nu10091289.

21.

Refined RIP-seq protocol for epitranscriptome analysis with low input materials.

Zeng Y, Wang S, Gao S, Soares F, Ahmed M, Guo H, Wang M, Hua JT, Guan J, Moran MF, Tsao MS, He HH.

PLoS Biol. 2018 Sep 13;16(9):e2006092. doi: 10.1371/journal.pbio.2006092. eCollection 2018 Sep.

22.

Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study.

Lee DH, Tsao MS, Kambartel KO, Isobe H, Huang MS, Barrios CH, Khattak A, de Marinis F, Kothari S, Arunachalam A, Cao X, Burke T, Valladares A, de Castro J.

PLoS One. 2018 Aug 27;13(8):e0202865. doi: 10.1371/journal.pone.0202865. eCollection 2018.

23.

A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium.

Lheureux S, Tinker A, Clarke B, Ghatage P, Welch S, Weberpals JI, Dhani NC, Butler MO, Tonkin K, Tan Q, Tan DSP, Brooks K, Ramsahai J, Wang L, Pham NA, Shaw PA, Tsao MS, Garg S, Stockley T, Oza AM.

Clin Cancer Res. 2018 Dec 15;24(24):6168-6174. doi: 10.1158/1078-0432.CCR-18-1244. Epub 2018 Aug 14.

PMID:
30108107
24.

Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer.

Devarakonda S, Rotolo F, Tsao MS, Lanc I, Brambilla E, Masood A, Olaussen KA, Fulton R, Sakashita S, McLeer-Florin A, Ding K, Le Teuff G, Shepherd FA, Pignon JP, Graziano SL, Kratzke R, Soria JC, Seymour L, Govindan R, Michiels S.

J Clin Oncol. 2018 Aug 14:JCO2018781963. doi: 10.1200/JCO.2018.78.1963. [Epub ahead of print]

PMID:
30106638
25.

Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk.

Ji X, Bossé Y, Landi MT, Gui J, Xiao X, Qian D, Joubert P, Lamontagne M, Li Y, Gorlov I, de Biasi M, Han Y, Gorlova O, Hung RJ, Wu X, McKay J, Zong X, Carreras-Torres R, Christiani DC, Caporaso N, Johansson M, Liu G, Bojesen SE, Le Marchand L, Albanes D, Bickeböller H, Aldrich MC, Bush WS, Tardon A, Rennert G, Chen C, Teare MD, Field JK, Kiemeney LA, Lazarus P, Haugen A, Lam S, Schabath MB, Andrew AS, Shen H, Hong YC, Yuan JM, Bertazzi PA, Pesatori AC, Ye Y, Diao N, Su L, Zhang R, Brhane Y, Leighl N, Johansen JS, Mellemgaard A, Saliba W, Haiman C, Wilkens L, Fernandez-Somoano A, Fernandez-Tardon G, van der Heijden EHFM, Kim JH, Dai J, Hu Z, Davies MPA, Marcus MW, Brunnström H, Manjer J, Melander O, Muller DC, Overvad K, Trichopoulou A, Tumino R, Doherty J, Goodman GE, Cox A, Taylor F, Woll P, Brüske I, Manz J, Muley T, Risch A, Rosenberger A, Grankvist K, Johansson M, Shepherd F, Tsao MS, Arnold SM, Haura EB, Bolca C, Holcatova I, Janout V, Kontic M, Lissowska J, Mukeria A, Ognjanovic S, Orlowski TM, Scelo G, Swiatkowska B, Zaridze D, Bakke P, Skaug V, Zienolddiny S, Duell EJ, Butler LM, Koh WP, Gao YT, Houlston R, McLaughlin J, Stevens V, Nickle DC, Obeidat M, Timens W, Zhu B, Song L, Artigas MS, Tobin MD, Wain LV, Gu F, Byun J, Kamal A, Zhu D, Tyndale RF, Wei WQ, Chanock S, Brennan P, Amos CI.

Nat Commun. 2018 Aug 13;9(1):3221. doi: 10.1038/s41467-018-05074-y.

26.

Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma.

Shi R, Li M, Raghavan V, Tam S, Cabanero M, Pham NA, Shepherd FA, Moghal N, Tsao MS.

Clin Cancer Res. 2018 Dec 1;24(23):5990-6000. doi: 10.1158/1078-0432.CCR-18-0717. Epub 2018 Aug 9.

PMID:
30093452
27.

The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.

Jao K, Tomasini P, Kamel-Reid S, Korpanty GJ, Mascaux C, Sakashita S, Labbé C, Leighl NB, Liu G, Feld R, Bradbury PA, Hwang DM, Pintilie M, Tsao MS, Shepherd FA.

Lung Cancer. 2018 Sep;123:22-29. doi: 10.1016/j.lungcan.2018.06.023. Epub 2018 Jun 19.

PMID:
30089591
28.

Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer.

Rotolo F, Zhu CQ, Brambilla E, Graziano SL, Olaussen K, Le-Chevalier T, Pignon JP, Kratzke R, Soria JC, Shepherd FA, Seymour L, Michiels S, Tsao MS.

Transl Lung Cancer Res. 2018 Jun;7(3):416-427. doi: 10.21037/tlcr.2018.05.01.

29.

Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through lncRNA PCAT19.

Hua JT, Ahmed M, Guo H, Zhang Y, Chen S, Soares F, Lu J, Zhou S, Wang M, Li H, Larson NB, McDonnell SK, Patel PS, Liang Y, Yao CQ, van der Kwast T, Lupien M, Feng FY, Zoubeidi A, Tsao MS, Thibodeau SN, Boutros PC, He HH.

Cell. 2018 Jul 26;174(3):564-575.e18. doi: 10.1016/j.cell.2018.06.014. Epub 2018 Jul 19.

PMID:
30033362
30.

Harmonization of PD-L1 testing in oncology: a Canadian pathology perspective.

Ionescu DN, Downes MR, Christofides A, Tsao MS.

Curr Oncol. 2018 Jun;25(3):e209-e216. doi: 10.3747/co.25.4031. Epub 2018 Jun 28. Review.

31.

Circulating tumour DNA in EGFR-mutant non-small-cell lung cancer.

Cabanero M, Tsao MS.

Curr Oncol. 2018 Jun;25(Suppl 1):S38-S44. doi: 10.3747/co.25.3761. Epub 2018 Jun 13. Review.

32.

Lung cancer in never smokers from the Princess Margaret Cancer Centre.

Korpanty GJ, Kamel-Reid S, Pintilie M, Hwang DM, Zer A, Liu G, Leighl NB, Feld R, Siu LL, Bedard PL, Tsao MS, Shepherd FA.

Oncotarget. 2018 Apr 27;9(32):22559-22570. doi: 10.18632/oncotarget.25176. eCollection 2018 Apr 27.

33.

PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.

Tsao MS, Kerr KM, Kockx M, Beasley MB, Borczuk AC, Botling J, Bubendorf L, Chirieac L, Chen G, Chou TY, Chung JH, Dacic S, Lantuejoul S, Mino-Kenudson M, Moreira AL, Nicholson AG, Noguchi M, Pelosi G, Poleri C, Russell PA, Sauter J, Thunnissen E, Wistuba I, Yu H, Wynes MW, Pintilie M, Yatabe Y, Hirsch FR.

J Thorac Oncol. 2018 Sep;13(9):1302-1311. doi: 10.1016/j.jtho.2018.05.013. Epub 2018 May 22.

PMID:
29800747
34.

The eighth TNM classification for lung cancer-What is next?

Tsao MS, Yoon JY.

Lung Cancer. 2018 Jul;121:97-98. doi: 10.1016/j.lungcan.2018.04.018. Epub 2018 Apr 25. No abstract available.

PMID:
29724454
35.

New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.

Galateau Salle F, Le Stang N, Nicholson AG, Pissaloux D, Churg A, Klebe S, Roggli VL, Tazelaar HD, Vignaud JM, Attanoos R, Beasley MB, Begueret H, Capron F, Chirieac L, Copin MC, Dacic S, Danel C, Foulet-Roge A, Gibbs A, Giusiano-Courcambeck S, Hiroshima K, Hofman V, Husain AN, Kerr K, Marchevsky A, Nabeshima K, Picquenot JM, Rouquette I, Sagan C, Sauter JL, Thivolet F, Travis WD, Tsao MS, Weynand B, Damiola F, Scherpereel A, Pairon JC, Lantuejoul S, Rusch V, Girard N.

J Thorac Oncol. 2018 Aug;13(8):1189-1203. doi: 10.1016/j.jtho.2018.04.023. Epub 2018 Apr 30.

PMID:
29723687
36.

Evidence-based best practices for EGFR T790M testing in lung cancer in Canada.

Stockley T, Souza CA, Cheema PK, Melosky B, Kamel-Reid S, Tsao MS, Spatz A, Karsan A.

Curr Oncol. 2018 Apr;25(2):163-169. doi: 10.3747/co.25.4044. Epub 2018 Apr 30.

37.

Helicase-like transcription factor expression is associated with a poor prognosis in Non-Small-Cell Lung Cancer (NSCLC).

Dhont L, Pintilie M, Kaufman E, Navab R, Tam S, Burny A, Shepherd F, Belayew A, Tsao MS, Mascaux C.

BMC Cancer. 2018 Apr 16;18(1):429. doi: 10.1186/s12885-018-4215-y.

38.

A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial.

Jonker DJ, Tang PA, Kennecke H, Welch SA, Cripps MC, Asmis T, Chalchal H, Tomiak A, Lim H, Ko YJ, Chen EX, Alcindor T, Goffin JR, Korpanty GJ, Feilotter H, Tsao MS, Theis A, Tu D, Seymour L.

Clin Colorectal Cancer. 2018 Sep;17(3):231-239.e7. doi: 10.1016/j.clcc.2018.03.001. Epub 2018 Mar 8.

PMID:
29653857
39.

Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC.

Melosky B, Chu Q, Juergens RA, Leighl N, Ionescu D, Tsao MS, McLeod D, Hirsh V.

Cancer Treat Rev. 2018 Apr;65:65-77. doi: 10.1016/j.ctrv.2018.02.005. Epub 2018 Feb 22. Review.

PMID:
29567557
40.

Multiplexed Real-Time NMR GTPase Assay for Simultaneous Monitoring of Multiple Guanine Nucleotide Exchange Factor Activities from Human Cancer Cells and Organoids.

Gebregiworgis T, Marshall CB, Nishikawa T, Radulovich N, Sandí MJ, Fang Z, Rottapel R, Tsao MS, Ikura M.

J Am Chem Soc. 2018 Apr 4;140(13):4473-4476. doi: 10.1021/jacs.7b13703. Epub 2018 Mar 22.

PMID:
29543440
41.

Translation of Knowledge to Practice-Improving Awareness in NSCLC Molecular Testing.

Zer A, Cutz JC, Sekhon H, Hwang DM, Sit C, Maganti M, Sung M, Binnie M, Brade A, Chung TB, Kamel-Reid S, Paul N, Tsao MS, Waddell T, da Cunha Santos G, Patel M, Carter RF, Leighl NB.

J Thorac Oncol. 2018 Jul;13(7):1004-1011. doi: 10.1016/j.jtho.2018.03.005. Epub 2018 Mar 11.

PMID:
29535011
42.

Genomic Testing in Lung Cancer: Past, Present, and Future.

Mascaux C, Tsao MS, Hirsch FR.

J Natl Compr Canc Netw. 2018 Mar;16(3):323-334. doi: 10.6004/jnccn.2017.7019. Review.

PMID:
29523671
43.

Correction to: Use of multicolor fluorescence in situ hybridization to detect deletions in clinical tissue sections.

Yoshimoto M, Ludkovski O, Good J, Pereira C, Gooding RJ, McGowan-Jordan J, Boag A, Evans A, Tsao MS, Nuin P, Squire JA.

Lab Invest. 2018 Jun;98(6):839. doi: 10.1038/s41374-018-0037-4.

PMID:
29520053
44.

Differentially expressed microRNAs in lung adenocarcinoma invert effects of copy number aberrations of prognostic genes.

Tokar T, Pastrello C, Ramnarine VR, Zhu CQ, Craddock KJ, Pikor LA, Vucic EA, Vary S, Shepherd FA, Tsao MS, Lam WL, Jurisica I.

Oncotarget. 2018 Jan 8;9(10):9137-9155. doi: 10.18632/oncotarget.24070. eCollection 2018 Feb 6.

45.

Standardizing biomarker testing for Canadian patients with advanced lung cancer.

Melosky B, Blais N, Cheema P, Couture C, Juergens R, Kamel-Reid S, Tsao MS, Wheatley-Price P, Xu Z, Ionescu DN.

Curr Oncol. 2018 Feb;25(1):73-82. doi: 10.3747/co.25.3867. Epub 2018 Feb 28.

46.

Eighth Edition Staging of Thoracic Malignancies: Implications for the Reporting Pathologist.

Nicholson AG, Tsao MS, Travis WD, Patil DT, Galateau-Salle F, Marino M, Dacic S, Beasley MB, Butnor KJ, Yatabe Y, Pass HI, Rusch VW, Detterbeck FC, Asamura H, Rice TW, Rami-Porta R.

Arch Pathol Lab Med. 2018 May;142(5):645-661. doi: 10.5858/arpa.2017-0245-RA. Epub 2018 Feb 26. Review.

PMID:
29480761
47.

Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly.

Costantini A, Grynovska M, Lucibello F, Moisés J, Pagès F, Tsao MS, Shepherd FA, Bouchaab H, Garassino M, Aerts JGJV, Mazières J, Mondini M, Berghmans T, Meert AP, Cadranel J.

Eur Respir J. 2018 Feb 14;51(2). pii: 1702072. doi: 10.1183/13993003.02072-2017. Print 2018 Feb.

PMID:
29444918
48.

The Integrated Genomic Landscape of Thymic Epithelial Tumors.

Radovich M, Pickering CR, Felau I, Ha G, Zhang H, Jo H, Hoadley KA, Anur P, Zhang J, McLellan M, Bowlby R, Matthew T, Danilova L, Hegde AM, Kim J, Leiserson MDM, Sethi G, Lu C, Ryan M, Su X, Cherniack AD, Robertson G, Akbani R, Spellman P, Weinstein JN, Hayes DN, Raphael B, Lichtenberg T, Leraas K, Zenklusen JC; Cancer Genome Atlas Network, Fujimoto J, Scapulatempo-Neto C, Moreira AL, Hwang D, Huang J, Marino M, Korst R, Giaccone G, Gokmen-Polar Y, Badve S, Rajan A, Ströbel P, Girard N, Tsao MS, Marx A, Tsao AS, Loehrer PJ.

Cancer Cell. 2018 Feb 12;33(2):244-258.e10. doi: 10.1016/j.ccell.2018.01.003.

49.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Ladanyi M, Nowak JA, Sholl L, Temple-Smolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Wynes MW, Yatabe Y.

J Mol Diagn. 2018 Mar;20(2):129-159. doi: 10.1016/j.jmoldx.2017.11.004. Epub 2018 Jan 23.

PMID:
29398453
50.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Ladanyi M, Nowak JA, Sholl L, Temple-Smolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Wynes MW, Yatabe Y.

J Thorac Oncol. 2018 Mar;13(3):323-358. doi: 10.1016/j.jtho.2017.12.001. Epub 2018 Jan 25.

Supplemental Content

Support Center